A prospective study of @entity1667 and XXXX as immunosuppressive agents in clinical renal transplantation.

@entity1 @entity1667 @entity295 @entity101 @entity229 @entity2348 @entity1017
A prospective double blind crossover study was carried out in 65 @entity1 comparing @entity1667 ( @entity1667 ) and @entity229 as immunosuppressive agents in clinical renal transplantation to determine their relative merits vis-a-vis graft survival, @entity101 , @entity1017 , @entity295 and @entity1 preference in the posttransplant period. @entity1 receiving renal allografts were randomly assigned to receive initial treatment with one of the drugs. Once maintenance doses were employed, the drug was switched for a 3-month period. There was no difference in overall graft survival at 1 year, 68% versus 56% (p greater than 0.4), for the two @entity1 groups. Likewise, there was no difference in blood pressure during the maintenance therapy crossover period, mean BP 129/86 during @entity1667 therapy and 129/86 during @entity229 therapy. Overall @entity1017 was not statistically different with the two drugs, 3.8 kg with @entity229 and 2.3 kg with @entity1667 , p greater than 0.1. However, when @entity1667 was used in the late posttransplant period, the @entity1 had a significantly smaller @entity1017 , 0.95 kg versus 3.5 kg with @entity229 , p greater than 0.05. The incidence of @entity2348 was significantly greater (p less than 0.02) during the early posttransplant period in those @entity1 treated with @entity1667 . Finally, the majority of @entity1 (65%) had no preference for either drug. Of those with a preference, the majority (69%) preferred @entity1667 . We conclude that therapy with @entity1667 does not offer superior graft survival, less @entity101 or overriding @entity1 preference but does apparently lead to an increased incidence of @entity2348 in the early posttransplant period. Thus it appears that @entity229 is the initial drug of choice as an immunosuppressive steroid in clinical renal transplantation.
